Literature DB >> 11880726

Adolescents with cancer: access to clinical trials and age-appropriate care.

Peter E Newburger1, Dianne S Elfenbein, Laurence A Boxer.   

Abstract

Many adolescents with cancer are denied the benefits of protocol inclusion and optimal supportive care. More than 70% of older adolescent patients are not treated at institutions representing pediatric cooperative groups and are not enrolled in clinical trials, despite a demonstrated survival advantage for patients registered in protocols. Failure to refer adolescent cancer patients to specialized pediatric oncology treatment centers also has an impact on their quality of care. The challenge before both the medical and pediatric health care communities is to assure adolescent patients the benefits of inclusion in clinical trials and treatment in age-appropriate settings.

Entities:  

Mesh:

Year:  2002        PMID: 11880726     DOI: 10.1097/00008480-200202000-00001

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  4 in total

1.  Making the invisible visible: professional education to eliminate disparities in clinical trials.

Authors:  Larry Laufman
Journal:  J Cancer Educ       Date:  2009       Impact factor: 2.037

2.  Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents.

Authors:  Meredith K Chuk; Yeruk Mulugeta; Michelle Roth-Cline; Nitin Mehrotra; Gregory H Reaman
Journal:  Clin Cancer Res       Date:  2016-10-25       Impact factor: 12.531

Review 3.  Ethical considerations in research involving children.

Authors:  Theresa A O'Lonergan; Henry Milgrom
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

4.  A cross-sectional survey of healthcare professionals to determine what they believe constitutes 'specialist' care for teenage and young adult patients with cancer.

Authors:  Rebecca J Birch; Eva J A Morris; Robert M West; Dan P Stark; Ian Lewis; Sue Morgan; Richard G Feltbower
Journal:  BMJ Open       Date:  2013-05-02       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.